Esperion – The Lipid Management Company

Esperion is a pharmaceutical company that specializes in developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The Company has two late-stage therapies in development; both with confirmed regulatory pathways to approval and defined global pivotal Phase 3 clinical development plans. Bempedoic acid and the Company’s lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies that have been shown to significantly reduce elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies.

Esperion Leadership has Strong Industry Expertise in Cholesterol Biology

Esperion has assembled an innovative team of lipid management experts who is exclusively committed to leveraging its scientific and clinical excellence and deep understanding of cholesterol biosynthesis. The team is focused on developing targeted, oral, non-statin LDL-C lowering therapies to address patient needs that have the potential to make a substantial impact on lowering LDL-C.

Our Mission: Developing Innovative Lipid-Modifying Therapies

Esperion is passionately committed to developing and commercializing convenient, complementary, consistent, oral LDL-C lowering therapies for patients with hypercholesterolemia and their physicians around the world. The bempedoic acid / ezetimibe combination pill and bempedoic acid are targeted, oral therapies that have been shown to significantly reduce elevated levels of LDL-C in patients inadequately treated with current lipid-modifying therapies. The Esperion-discovered and developed bempedoic acid-based therapies are “patient-friendly, physician-friendly, and payer-friendly”.

Our Core Values

We promote an inclusive and supportive environment that, regardless of title or rank, fosters open discussion and debate.
We are committed to making a difference for patients living with hypercholesterolemia and will confront every challenge with optimism and resourcefulness.
We challenge the status quo with entrepreneurial spirit as we remain steadfastly committed to problem solving with agility, resilience, and creativity.
We hold ourselves and each other to the highest level of personal and professional integrity, by owning what we say and delivering on our commitments.
We value each other and we invest in building strong relationships and creating opportunities for personal and professional growth.